Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

„Qality by design“ – plánované řízení kvality ve farmaceutickém průmyslu
[Quality by design – planned quality management in pharmaceutical industry]

Michal Beneš

. 2017 ; 111 (9) : 559-566.

Jazyk čeština Země Česko

Typ dokumentu přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17033755

Quality by design is a systematic approach to drug product development and manufacturing that starts by defining the target product quality. It continues with an assessment of the risks to product quality that are involved in the characteristics of the raw materials and in the parameters of the manufacturing process. At the following stage, the actual impact of the characteristics and parameters identified is found through experiments and the design space is defined on that basis. Design space is an abstract multidimensional space in which the desired product quality can be attained by changing and controlling the variables. Based on the advanced knowledge of the product and the process obtained, the process can be optimized effectively and an appropriate control strategy set at points representing the greatest risk to quality or at points where information can be obtained well enough in advance to allow for reversing (by an appropriate adjustment of the process conditions) a potentially inappropriate course of the process. The information gained through the use of quality-by-design tools can then be used to accelerate the registration process of a new drug product and, in particular, for a substantial increase of manufacturing process efficiency and of the certainty that the desired product quality will be achieved.

Quality by design – planned quality management in pharmaceutical industry

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc17033755
003      
CZ-PrNML
005      
20180611125114.0
007      
ta
008      
171128s2017 xr a f 000 0|cze||
009      
AR
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Beneš, Michal $7 _AN093830 $u Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové, Katedra farmaceutické technologie, Heyrovského 1203, 500 05 Hradec Králové
245    10
$a „Qality by design“ – plánované řízení kvality ve farmaceutickém průmyslu / $c Michal Beneš
246    31
$a Quality by design – planned quality management in pharmaceutical industry
504    __
$a Literatura
520    9_
$a Quality by design is a systematic approach to drug product development and manufacturing that starts by defining the target product quality. It continues with an assessment of the risks to product quality that are involved in the characteristics of the raw materials and in the parameters of the manufacturing process. At the following stage, the actual impact of the characteristics and parameters identified is found through experiments and the design space is defined on that basis. Design space is an abstract multidimensional space in which the desired product quality can be attained by changing and controlling the variables. Based on the advanced knowledge of the product and the process obtained, the process can be optimized effectively and an appropriate control strategy set at points representing the greatest risk to quality or at points where information can be obtained well enough in advance to allow for reversing (by an appropriate adjustment of the process conditions) a potentially inappropriate course of the process. The information gained through the use of quality-by-design tools can then be used to accelerate the registration process of a new drug product and, in particular, for a substantial increase of manufacturing process efficiency and of the certainty that the desired product quality will be achieved.
650    12
$a farmaceutický průmysl $x metody $x organizace a řízení $7 D004345
650    _2
$a směrnice jako téma $7 D017408
650    12
$a kontrola léčiv a omamných látek $x organizace a řízení $7 D004335
650    12
$a příprava léků $7 D004339
650    _2
$a řízení kvality $7 D011786
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a statistika jako téma $7 D013223
653    00
$a optimalizace
653    00
$a Quality by design
655    _2
$a přehledy $7 D016454
773    0_
$t Chemické listy $x 0009-2770 $g Roč. 111, č. 9 (2017), s. 559-566 $w MED00011010
856    41
$u http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/41/41 $y domovská stránka časopisu
910    __
$a ABA008 $b B 1918 $c 395 $y 4 $z 0
990    __
$a 20171127085132 $b ABA008
991    __
$a 20180611125326 $b ABA008
999    __
$a ok $b bmc $g 1260674 $s 994810
BAS    __
$a 3
BMC    __
$a 2017 $b 111 $c 9 $d 559-566 $i 0009-2770 $m Chemické listy $n Chem. Listy $x MED00011010
LZP    __
$c NLK185 $d 20180611 $a NLK 2017-49/vt

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...